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All cancers tested so far display abnormal choline and ethanolamine phospholipid
metabolism, which has been detected with numerous magnetic resonance spectros-
copy (MRS) approaches in cells, animal models of cancer, as well as the tumors of 
cancer patients. Since the discovery of this metabolic hallmark of cancer, many studies 
have been performed to elucidate the molecular origins of deregulated choline metab-
olism, to identify targets for cancer treatment, and to develop MRS approaches that 
detect choline and ethanolamine compounds for clinical use in diagnosis and treatment 
monitoring. Several enzymes in choline, and recently also ethanolamine, phospholipid 
metabolism have been identified, and their evaluation has shown that they are involved in 
carcinogenesis and tumor progression. Several already established enzymes as well as 
a number of emerging enzymes in phospholipid metabolism can be used as treatment 
targets for anticancer therapy, either alone or in combination with other chemothera-
peutic approaches. This review summarizes the current knowledge of established and 
relatively novel targets in phospholipid metabolism of cancer, covering choline kinase α, 
phosphatidylcholine-specific phospholipase D1, phosphatidylcholine-specific phospho-
lipase C, sphingomyelinases, choline transporters, glycerophosphodiesterases, phos-
phatidylethanolamine N-methyltransferase, and ethanolamine kinase. These enzymes 
are discussed in terms of their roles in oncogenic transformation, tumor progression, 
and crucial cancer cell properties such as fast proliferation, migration, and invasion. Their 
potential as treatment targets are evaluated based on the current literature.
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iNTRODUCTiON
Phospholipids, which form the bilayer structures of all cellular membranes, are an essential com-
ponent of all cells. The phospholipid content was shown to increase with cell transformation and 
tumor progression (1–4). For example, lipid analyses of samples from breast cancer tissue displayed 
an increase in phospholipid content as compared to non-cancerous adjacent healthy breast tissue 
(5). Concentrations of the two major phospholipid components phosphatidylcholine (PtdCho) 
and phosphatidylethanolamine (PtdEtn) increased with increasing breast cancer tumor grade (6), 
indicating that the phospholipid synthesis rate increases with oncogenesis and tumor progression 
as compared to normal tissue.
Metabolic intermediates of PtdCho metabolism were consistently observed to display abnor-
mal levels with magnetic resonance spectroscopy (MRS) (7). An increased total choline (tCho) 
signal, which consists of signals from phosphocholine (PC), glycerophosphocholine (GPC), and 
FigURe 1 | Biochemical network of ethanolamine and choline phospholipid metabolism showing crosstalk between these two metabolic cycles. MR 
detectable metabolites are drawn in boxes. Red shapes show enzymes discussed in this review, and green shapes show other enzymes responsible for the 
indicated reactions, but not discussed in this review. Metabolite abbreviations: 1-acyl-GPE, 1-acyl-glycerophosphoethanolamine; 1-acyl-GPC, 1-acyl-
glycerophosphocholine; PtdCho, phosphatidylcholine; PtdEth, phosphatidylethanolamine; SM, sphingomyelin. Enzyme abbreviations: CCT, phosphocholine 
cytidylyltransferase; ChK, choline kinase; CPT, diacylglycerol cholinephosphotransferase; CTL, choline transporter-like protein; EtT, ethanolamine transporter; ECT, 
phosphoethanolamine cytidylyltransferase; EPT, diacylglycerol ethanolaminephosphotransferase; ETNK, ethanolamine kinase; GPE-PDE, 
glycerophosphoethanolamine phosphodiesterase; GDPD6, glycerophosphodiester phosphodiesterase domain containing 6; lyso-PL, lysophospholipase; PEMT, 
phosphatidylethanolamine N-methyltransferase; PLA2, phospholipase A2; PLC, phospholipase C; PLD, phospholipase D.
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free choline (Cho), and whose chemical structures are shown in 
Figure 1, has been detected by 1H MRS in all cancers tested so 
far (7). High-resolution 1H MRS, which can resolve the signals 
from the individual components of the tCho signal, confirmed 
the increase of PC in breast (8–12), prostate (13, 14), ovarian (15), 
endometrial (16), cervical (15), and brain cancers (17–19). In 
some cancer cell types such as isolated breast and ovarian cancer 
cells, a relative decrease of GPC was observed as well, which led 
to the suggestion to use a higher ratio of PC/GPC as a marker 
of tumor progression (20, 21). PC was also reported as a useful 
imaging biomarker of tumor response to several targeted treat-
ments of cancers, enabling 1H MRS to be used for monitoring 
changes in PC as a non-invasive marker of pharmacodynamic 
treatment response (22–26). A PC decrease and GPC increase 
was reported after docetaxel treatment in breast cancer cell lines 
and xenograft models (27).
Magnetic resonance spectroscopy detection of tCho allows 
for non-invasive and longitudinal monitoring of deep-seated 
tumors, and it is currently being evaluated as non-invasive bio-
marker for cancer diagnosis, monitoring of treatment response, 
and anticancer drug development. In clinical studies, in  vivo 
MRS detection of the tCho signal was proposed as a marker of 
breast cancer malignancy (8, 28–31). The tCho signal has been 
used to monitor neoadjuvant chemotherapy of breast tumors 
in patients (32), and decreased tCho was associated with the 
pathology-detected tumor response to chemotherapy (10, 12, 33). 
One limitation of using choline-based 1H MRS is the difficulty 
of resolving the signals of PC and GPC and free choline in the 
in vivo 1H MRS setting.
Phosphorus MRS (31P MRS) is also able to detect phospholipid 
metabolites and displays two sets of phospholipid metabolite 
peaks: phosphomonoesters (PMEs), which are mainly composed 
of PC and PE (phosphoethanolamine), and diphosphodiesters, 
with GPC and GPE (glycerophosphoethonolamine) as the main 
components as shown in Figure 2. Early 31P MRS cancer studies, 
which were not able to separate the individual components of 
FigURe 2 | example of in vivo pulse-acquire (PA, top) and BiNePT (bottom) 31P MR spectra of a representative MCF-7 (left) and MDA-MB-231 (right) 
tumor. Lorentzian lines as fitted by the software jMRUI (http://www.jmrui.eu/) are shown below each MR spectrum. All phosphorylated metabolites are visible in the 
PA spectrum, whereas the BINEPT spectrum only contains signals from phospholipid metabolites with H-P-coupling such as phosphoethanolamine (PE), 
phosphocholine (PC), glycerophosphoethanolamine (GPE), and glycerophosphocholine (GPC). Note the broad, uneven baseline in the 0–5 ppm region of the PA 
spectra, where signals from mobile membrane phospholipids are resonating. The signal of β-nucleoside triphosphate (NTP) is formed by β-NTP only. The signal 
labeled α-NTP is an overlapping signal from α-NTP, α-nucleoside diphosphate (α-NDP), nicotinamide adenine diphosphate, and diphosphodiesters. The signal 
labeled γ-NTP is an overlapping signal from γ-NTP and β-NDP. Typically, β-NTP is the smallest peak of the three NTP signals; however, here, γ-NTP overlaps with a 
broad baseline signal that makes it appear smaller than β-NTP. Adapted from Wijnen et al. (44).
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these two sets of 31P peaks very well, detected that PMEs were 
increased in human breast tumors (34–37), neuroblastomas (38), 
prostate cancers (39), and hepatic lymphomas (40) as compared 
to corresponding normal tissues. Following chemotherapy or 
radiotherapy, a PME reduction was observed in human neuro-
blastoma (38), breast tumors (35, 36), and hepatic lymphoma 
(40). Recent developments of innovative 31P MRS approaches that 
are based on 1H to 31P polarization transfer enable the quantifica-
tion of in vivo levels of PE, PC, GPE, and GPC on small animal 
and clinical MR scanners (41–44). PE and GPE are the metabolic 
intermediates of PtdEtn, the second most abundant phospho-
lipid. PE was found to consistently increase in tumors similar to 
PC (see Figure 2) (45), although its role in cancers is much less 
explored than PC. The potential of PE and GPE to be monitored 
is currently being explored along with PC and GPC (41, 44). The 
changes that occur in tCho, PMEs, and PDEs with oncogenesis 
and in response to therapy are the result of complex molecular 
pathways and are therefore not always consistent (8, 37, 46, 47), 
making it necessary to improve the resolution of clinical in vivo 
MRS applications and to investigate the molecular mechanism 
underlying these metabolic changes.
Choline uptake and retention can also be imaged using positron 
emission tomography (PET), mainly with the tracers [11C]-choline, 
[18F]-fluoromethylcholine, and [18F]-fluoroethylcholine. The use 
of [11C]-choline PET was approved for clinical use in prostate can-
cer by the federal drug administration of the United States in 2012 
(48). Choline PET/computed tomography (CT) is used in the 
clinic as well and has the advantages of providing improved local 
disease evaluation and staging of prostate cancer as compared 
to conventional [18F]-FDG PET, giving additional information 
on nodal staging and suspected metastasis in prostate cancer 
patients (49).
While choline-based imaging has been explored extensively, 
discoveries of genes and signaling pathways leading to the 
changes in choline-containing metabolites are still emerging. 
The function and regulation of the two enzymes choline kinase 
α (ChKα) and phospholipase D (PLD) has been more widely 
explored in cancer, but research into other important enzymes in 
choline metabolism is still at an early stage. These enzymes may 
provide new targets for cancer therapy. In this review, we will 
provide a brief update on the established targets in choline phos-
pholipid metabolism and discuss some new anticancer targets in 
the choline and ethanolamine phospholipid metabolic pathways 
as highlighted in red in Figure 1.
CHOLiNe KiNASe α
Choline kinase is the enzyme that phosphorylates free choline 
and produces PC. There are two genes that encode this enzyme: 
ChKα and choline kinase beta (ChKβ) (50–52). ChKα is well 
established as an oncogene that promotes tumor initiation and 
progression (7, 53, 54). Its overexpression and elevated enzyme 
activity is one of the most established factors that contribute to 
increased PC and tCho in various tumor tissues including breast 
FigURe 3 | Choline kinase α (ChKα) as target for anticancer treatment. (A) ChKα converts free choline to phosphocholine (PC). (B) Knockdown of ChKα 
resulted in a dramatic reduction of cellular PC as evident by the decreased PC signal in high-resolution 1H MR spectrum obtained from water-soluble metabolites of 
MDA-MB-231 cells transfected with anti-ChKα siRNA compared to the spectrum from non-target siRNA control. (C) Stable knockdown of ChKα with a pSHAG-U6-
shRNA vector significantly decreased MDA-MB-231 cell growth rate. Abbreviations: GPC, glycerophosphocholine. ***represents P < 0.001, average proliferation 
rates were calculated from five independent experiments. Adapted from Glunde et al. (69).
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(55), ovarian (21), colorectal (56), prostate (56), lung (56, 57), 
endometrial (16), and pancreatic (58) cancer.
In addition to catalyzing the formation of PC in the Kennedy 
pathway of PtdCho synthesis, ChKα also has other functions in 
regulating cell signaling pathways. For example, the non-receptor 
tyrosine kinase c-Src was shown to phosphorylate ChKα, which in 
turn forms a protein complex with epidermal growth factor recep-
tor to regulate breast cancer cell proliferation and tumorigenesis 
(59). Downregulation of ChKα decreased the phosphorylation of 
the mitogen-activated protein kinase (MAPK) signaling pathway 
protein ERK1/2 to p-ERK1/2 on T202/Y204 (60), and the PI3K/
AKT signaling pathway protein AKT to p-AKT on S473 (61). 
ChKα inhibition induced exacerbated endoplasmic reticulum 
(ER) stress and triggered apoptosis via the CHOP pathway in 
cancer cells, but not in the non-tumorigenic mammary epithe-
lial cell line MCF-10A (62). CHOP is the major pro-apoptotic 
transcription factor that is induced by ER stress. Inhibition of 
ChKα in cancer cells also resulted in an intracellular increase in 
ceramides, leading to apoptotic cell death, suggesting that ChKα 
activity disruption may be a highly specific and selective cytotoxic 
antitumoral strategy. ChKα knockout mice, but not knockout 
mice with a loss of ChKβ, are embryonically lethal, implying that 
ChKα is essential for PtdCho biosynthesis (7, 63, 64).
Several small molecule inhibitors of ChKα- and siRNA-based 
nanoparticles have been developed to test their potential for MRS-
monitored anticancer treatment. Lacal and colleagues have tested 
several groups of compounds that inhibit ChKα activity, some 
of which displayed significant levels of antiproliferative activity 
and led to a reduction of tumor growth (65–67). One of these 
inhibitors, TCD-717 (68), is currently being tested in a phase I 
clinical trial (https://clinicaltrials.gov/ct2/show/NCT01215864). 
Bhujwalla and colleagues have developed siRNA and shRNA strat-
egies (Figure 3) (69, 70), and siRNA-based nanoparticles against 
ChKα (71) for anticancer therapy. Both methods of therapy can be 
monitored by detecting ChKα activity with MRS (22, 69, 70, 72). 
siRNA silencing of ChKα demonstrated synergistic effects with 
5-fluorouracil (5-FU) in the treatment of breast cancer cells 
(73), and ChKα inhibitors showed similar effects in preclinical 
studies of treating colorectal cancer (74). Overall, ChKα is a 
well-established antitumor target, with multiple inhibitors and 
siRNA-based agents against ChKα under development and in 
initial clinical testing phases. It is possible that ChKα may enter 
clinical application as stand-alone treatment or in combination 
with other first-line chemotherapeutic drugs such as 5-FU. MRS 
monitoring of tumor tCho or PME levels in patients undergoing 
treatment with ChKα-targeted drugs may facilitate non-invasive 
assessment of tumor response for more precise treatment moni-
toring and dynamic adjustment of the treatment plan.
PtdCho-SPeCiFiC PHOSPHOLiPASe  
D (PLD)
The phospholipase D enzyme hydrolyzes the most abundant 
phospholipid PtdCho and thereby produces phosphatidic acid 
(PA) and free choline (75). PA is a second messenger that directly 
binds to the mammalian target of rapamycin (mTOR) (76). PA 
can also be converted to other secondary messengers such as 
FigURe 4 | Phospholipase D1 activity in the tumor microenvironment 
is important for tumor growth and metastasis. (A) Representative 
picture showing that melanoma xenografts grown in Pld−/− mice have limited 
growth volume compared to that growing in wild-type (WT) mice. Scale bar, 
1 cm. (B) Melanoma xenografts growing in Pld−/− mice have fewer blood 
vessels as compared to those grown in wild-type mice, as evident from H&E 
stains of the respective tumor sections. Arrowheads in panel (B) indicate 
blood vessels. Scale bar, 50 µm. (C) For melanoma xenografts, lung 
metastasis has been significantly lower in lungs of Pld−/− mice than in lungs of 
wild-type mice. Adapted from Chen et al. (94).
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diacylglycerol (DAG) by lipid phosphatidate phosphatase, or to 
lysophosphatidic acid (LPA) by phospholipase A2 (75). There are 
two isoforms of PLD in the human genome: phospholipase D1 
(PLD1) and PLD2, which share 50% amino acid identity and dis-
play a similar protein structure (77, 78). PLD1, PLD2, and PA have 
been reported to interact with several protein partners, forming a 
molecular network that mediates various cellular functions (79). 
These cellular functions include vesicle trafficking (endocytosis 
and exocytosis), trans-Golgi network vesicle formation, cytoskel-
eton organization, cell migration, cell morphogenesis, autophagy 
(80), and the regulation of growth, proliferation, survival, and 
apoptosis (81).
Elevated PtdCho-specific PLD activity and/or increased 
expression of PLD1 or PLD2 have been observed in many differ-
ent types of cancer and in transformed cells. A single-nucleotide 
polymorphism without protein change in PLD1 was reported to 
increase the risk of small cell lung cancer (82). A polymorphism 
in PLD2 is associated with the prevalence of colorectal cancer 
(83). Overexpression of either PLD1 or PLD2 in murine fibro-
blasts alters their cell growth, confers anchorage-independent 
growth ability in soft agar, and sarcoma formation in nude mice 
(84). Genetically enforced overexpression of PLD1 or PLD2 in 
a human breast cancer xenograft model led to primary tumor 
initiation and increased metastasis (85). PLD activity was shown 
to confer rapamycin resistance in human breast cancer cells (86). 
PLD activity was also demonstrated to couple survival and migra-
tion signals in human cancer cells to stress response (87). PLD1 
and ChKα are interactive, such that ChKα silencing increases 
PLD1 expression and PLD1 silencing increases ChKα expression 
(88). The contributions of PLD to cancer have been summarized 
by Bruntz et al. as sustaining proliferative signaling, transducing 
MAPK signaling, regulating mTOR, evading growth suppression, 
resisting apoptosis- or autophagy-mediated cell death, activating 
invasion and metastasis, inducing angiogenesis, and deregulating 
cellular energetics (81).
Targeting PLD for anticancer therapy has been extensively 
explored. siRNA silencing or genetic ablation of either PLD1 or 
PLD2 were demonstrated to reduce cell proliferation, cell migra-
tion, and/or xenograft growth (85, 89). In ApcMin/+ and azox-
ymethane/dextran sodium sulfate (AOM/DSS) mouse models, 
spontaneous and colitis-associated intestinal tumorigenesis was 
reported to be disrupted by genetic or pharmacological targeting of 
PLD1, but not PLD2 (90). This was the case because PLD1 inactiva-
tion suppressed the self-renewal capacity of colon cancer-initiating 
cells, which in turn decreased the expression of β-catenin (90). 
The combination of PLD1 and autophagy inhibition was shown to 
synergize in inducing tumor cell apoptosis and tumor regression, 
providing a potential rational target for anticancer therapy (91). 
In earlier studies, short-chain primary alcohols were used as PLD 
inhibitor, but concerns were raised about insufficient suppression 
of PA production and off-target effects (92). Several PLD-specific 
inhibitors have been screened and evaluated in preclinical studies 
(81, 92, 93). 5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), 
a dual inhibitor of PLD1 and PLD2 (93), has shown anticancer 
potential. Delivering FIPI with an osmotic pump to a xenograft 
model of breast cancer in mice was able to inhibit primary tumor 
growth and reduce metastatic growth of nodules in the axillary 
lymph nodes and lungs (85). Tumors grew more slowly in FIPI-
treated mice and showed a significant decrease in microvessel 
density as compared to non-treated control mice (94). Later stud-
ies have explored the anticancer properties of isoform-selective 
inhibitors of PLD1 or PLD2 (95). The PLD1 selective inhibitor 
VU0155069 was shown to attenuate intestinal tumorigenesis in 
the ApcMin/+ and AOM/DSS mouse models (90). Both PLD1 
and PLD2 selective inhibitors were found to enhance the radio-
sensitivity of breast cancer cells (96).
The generation of PLD1-deficient transgenic mice provided 
the opportunity of studying the role of PLD1 in the tumor 
microenvironment. Tumor xenografts growing in Pld1−/−, but 
not in Pld2−/−, mice were demonstrated to have limited primary 
tumor growth and reduced lung metastasis as shown in Figure 4 
(94). Further examination showed that vascular endothelial cells 
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of PLD1-deficient mice displayed reduced activities in signal-
ing pathways that affect vascular endothelial growth factor as a 
downstream target (94). These signaling pathways were mediated 
by reduced phosphorylation of Akt, the MAPK proteins ERK1/2, 
and P38, leading to decreased integrin-dependent cell adhesion to 
and migration on extracellular matrices, as well as reduced tumor 
angiogenesis (Figure  4B) (94). Partly mediated by impaired 
activation of αIIbβ3 integrin in platelets, tumor cell–platelet inter-
actions decreased in Pld1−/− mice, resulting in reduced seeding 
of tumor cells into the lung parenchyma (Figure 4C) (94). Small 
molecule inhibitors of PLD1 displayed similar effects on tumors 
as the genetic ablation of PLD1 in the host mice (94).
Both Pld1−/− and Pld2−/− mice developed overtly normal (80, 
97, 98), indicating that PLD1 inhibitors may have low toxicity. 
Although the existing small molecule inhibitors against PLD1 
only impair cell migration and under-perform in killing cancer 
cells or reducing the proliferation rate of cancer cells as a stand-
alone treatment, they may synergize well with other therapy 
approaches in combatting cancers, due to PLD1’s multiple roles 
in important cell functions. Moreover, PLD1’s role in the tumor 
microenvironment, which confers the ability to disrupt tumor 
angiogenesis in some studies (94), makes it an attractive target. 
Although no PLD1 inhibitors have entered into clinical trials for 
anticancer therapy yet, promising results emerging from recent 
preclinical studies may pave the way for PLD1 inhibitors into 
clinical studies in the near future.
PHOSPHATiDYLCHOLiNe-SPeCiFiC 
PHOSPHOLiPASe C (PtdCho-PLC)
Phosphatidylcholine-specific phospholipase C cleaves the PC 
moiety from PtdCho, thereby generating and releasing DAG and 
PC into cytosol. DAG is an important second messenger that acti-
vates protein kinase C and induces mitogenic signal transduction. 
Considering the large abundance of PtdCho, it is possible that 
PtdCho-PLC hydrolysis of phospholipids can produce a more 
sustained DAG elevation than phosphatidylinositol-specific PLC 
cleavage of phosphatidylinositol (99). The sustained mitogenic 
signal produced by PtdCho-PLC generated DAG may lead to cell 
transformation. Indeed, NIH3T3 fibroblasts stably transfected 
with bacterial PtdCho-PLC displayed chronically elevated levels 
of DAG and PC, and a transformed phenotype that was charac-
terized by anchorage-independent growth in soft agar, formation 
of transformed foci in tissue culture, and loss of contact inhibition 
(100). Increased PtdCho-PLC enzyme activity was observed in 
ovarian cancer cells (101, 102), breast cancer cells (103), and 
squamous cell carcinoma cells (104) as compared to the cor-
responding non-malignant, immortalized cells. PtdCho-PLC 
selectively accumulated in raft domains in the plasma membrane 
of HER2-overexpressing breast cancer cells, in which it colocal-
ized with HER2 (105).
Since the genes encoding PtdCho-PLC have not yet been 
cloned from mammalian genomes, it is currently not possible to 
genetically ablate PtdCho-PLC activity, and mechanistic PtdCho-
PLC studies have to rely on small molecule inhibitors of PtdCho-
PLC, such as tricyclodecan-9-yl-potassium xanthate (D609). 
D609 competitively inhibits PtdCho-PLC activity and was 
shown to confer antiviral and antitumor effects (106). Inhibition 
of PtdCho-PLC with D609 reduced the cellular PC content and 
blocked cell proliferation in human ovarian cancer cells (102). 
D609 treatment of human MDA-MB-231 breast cancer cells led 
to a loss of mesenchymal traits, such as decreased Vimentin and 
N-Cadherin expression, and a changed cell morphology more 
similar to mature breast epithelial cells, as well as growth arrest 
and reduced migration and invasion potential (103). PtdCho-
PLC inhibition with D609 also resulted in enhanced HER2 
internalization and lysosomal degradation, strong retardation of 
HER2 re-expression on the membrane, and reduced HER2 con-
tent in HER2-overexpressing breast cancer cells, suggesting that 
PtdCho-PLC inhibitors may be potential candidates for the treat-
ment of HER2-amplified or trastuzumab-resistant breast cancers 
(105). D609 treatment of the two squamous cell carcinoma cell 
lines A431 and CaSki, which display different stemness potential, 
led to reduced cell proliferation, decreased sphere-forming effi-
ciency, and down-modulated mRNA levels of stemness-related 
markers (104). Although the mammalian PtdCho-PLC genes 
have not yet been identified, it is evident that PtdCho-PLC activ-
ity is important in cell transformation and cancer progression, 
and that inhibiting PtdCho-PLC activity may have potential as an 
anticancer strategy. Efforts should focus on cloning mammalian 
PtdCho-PLC gene(s) and identifying compounds that inhibit 
PtdCho-PLC and are suitable for clinical application.
SPHiNgOMYeLiNASeS (SMAs)
Sphingomyelin is a sphingosine-based phospholipid that exists in 
cell membranes with a typical mole percentage of around 10–20 
(107). Sphingomyelin typically contains a PC or sometimes a PE 
headgroup similar to glycerol-based phospholipids. SMAs are 
enzymes that act analogous to phospholipase C, release PC or 
PE from sphingomyelin, and thereby generate ceramide (108). 
According to the pH for their optimum enzyme function, they are 
classified as acidic, neutral, and alkaline SMAs (109).
The importance of acid sphingomyelinase (ASM) function in 
tumor irradiation has been well established with genetic stud-
ies (110). Niemann–Pick patients have an inherited deficiency 
of ASM activity, which results in their lymphoblasts failing to 
respond to ionizing radiation with ceramide generation and 
apoptosis (110). ASM knockout mice also displayed failure of 
radiation-induced ceramide generation and apoptosis in  vivo 
(110). MCA/129 fibrosarcomas and B16F1 melanomas grown in 
ASM-deficient mice grow much faster than in control mice and 
showed reduced endothelial apoptosis upon irradiation (111). 
When these cells were grown in severe combined immunodeficient 
mice with ASM-deficiency, the xenografts acquired resistance to 
single-dose radiotherapy (112), implying that ASM-mediated, 
radiotherapy-induced apoptosis occurs both in cancer cells and 
in the tumor microenvironment. Production of ceramide after 
tumor irradiation or treatment with chemotherapeutic agents, 
including commonly used daunorubicin, doxorubicin, cisplatin, 
paclitaxel, gemicitabine, among others, is a well-known treatment 
response (113). The production of ceramide through hydrolysis of 
sphingomyelin by ASM following chemotherapy is an important 
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mechanism of cellular ceramide increase which leads to tumor 
cell apoptosis, as siRNA knockdown of ASM prevents cancer cell 
death induced by cisplatin (114) or gemcitabine (115, 116).
The molecular mechanism by which ASM promotes cell apop-
tosis is mainly through its ceramide-producing ability. Moreover, 
the formation of ceramide-enriched lipid domains can trap and 
cluster specific membrane receptors such as CD95 and intracel-
lular signaling molecules, and thus, facilitate cellular signal trans-
duction, which leads to apoptosis, autophagic responses, and cell 
cycle arrest (114, 117, 118). To improve the therapeutic efficacy 
of ceramide-producing chemotherapy, further increasing the 
ceramide generation in cancer cells through activation of SMAs 
may be a worthwhile strategy to enhance anticancer treatment. 
However, it is generally hard to activate protein function. On the 
contrary, most rational drug design strategies inhibit rather than 
activate protein function. Based on this reasoning, ASM does not 
seem to be a suitable anticancer target at first sight. However, on 
the other hand, ASM-deficient human patients suffering from 
Niemann–Pick disease have cells with lysosomal storage disorders 
and significantly decreased lysosomal stability (119), suggesting 
that ASM is essential for maintaining normal lysosomal integrity. 
To escape from apoptosis, tumor cells, especially therapy resistant 
cancer cells, probably decrease their ASM activity to a critically 
low level, making them more sensitive than normal cells to 
ASM inhibition that can lead to lysosomal destabilization (120). 
Siramesine and several clinically relevant ASM inhibitors were 
found to trigger cancer-selective lysosomal cell death, displaying 
great anticancer potential as evident by reducing tumor growth 
in vivo, and reverting multidrug resistance (Figure 5) (121). So 
the strength of escaping from apoptosis by decreasing ASM levels 
becomes a weakness of cancers, through which cancer-specific 
killing agents can be developed especially for malignant and 
multidrug-resistant cancers (122).
There are several genes in the mammalian genome encoding 
neutral sphingomyelinases (N-SMase): the nSMase1 gene most 
likely encodes a lyso-platelet activating factor with phospholipase 
C activity (123), the nSMase2 and nSMase3 genes encode bona 
fide SMAs (124), and the newly identified MA-nSMase is a 
mitochondria-associated protein (125). Similar to ASM, N-SMase 
activity also promotes apoptosis through production of ceramide 
(124). The antitumoral chemotherapeutic reagents daunorubicine 
and arabinoside-C activate N-SMase in leukemic cells, resulting 
in ceramide release, which activates Jun-N-terminal kinases and 
Lyn protein tyrosine kinase to mediate cell apoptosis (126–128). 
Doxorubicin also induces nSMase2 mRNA and protein in a 
dose-dependent manner, and nSMase2 knockdown can prevent 
doxorubicin-induced growth arrest (129).
Alkaline sphingomyelinase activity is mostly found in 
the gastrointestinal tract and in human bile (130), and it is 
associated with colon cancer. Early studies showed that dietary 
sphingomyelin intake inhibited the formation of colon cancer 
that was induced with the carcinogen 1,2-dimethylhydrazine 
in mice (131). Both, human colorectal carcinoma and familial 
adenomatous polyposis, display a marked reduction in alkaline 
sphingomyelinase activity (130, 132, 133). Knockout of the alka-
line sphingomyelinase encoding gene NPP7 in mice significantly 
enhanced colonic tumorigenesis as compared to wild-type mice, 
after both groups of mice had been treated with a carcinogenic 
formulation of azoxymethane and dextran sulfate sodium (134). 
Loss of function mutated NPP7 gene copies were identified in the 
colon cancer cell line HT-29, the liver cancer cell line HepG2, and 
in liver tumor tissues (135, 136).
In summary, the family of SMAs generally acts in an anti-
cancer role through ceramide release leading to apoptosis. 
Radiation therapy, chemotherapeutic agents, and some targeted 
therapy inhibitors exerted their tumor killing ability by activating 
sphingomyelinase enzyme activity. The functioning of ASM in 
lysosomal integration has lead to the concept of inhibiting ASM 
to destabilize lysosomes and kill cancer cells (120, 122). The 
cationic amphiphilic drug siramesine, initially developed as an 
anti-depression agent which failed for having no effect, may be 
alternatively developed as an anticancer drug, and may be particu-
larly successful when combined with microtubule-destabilizing 
antimitotic drugs (137). To date, the effects of sphingomyelinase 
activation or inhibition on the choline metabolite profile and 
tCho levels have not yet been studied.
CHOLiNe TRANSPORTeRS
The accelerated synthesis of PtdCho to satisfy the need of fast 
proliferation of cancer cells requires a large quantity of choline as 
precursor. Cancer cells typically take up free choline from their 
environment, which in some cases is a rate-limiting step in form-
ing PC and in the Kennedy pathway (138). Free choline, which is 
an organic cation, cannot cross cell membranes freely, and hence 
requires active transporters for its import into cells. The human 
genome has four groups of proteins with choline transport ability: 
choline transporter 1 (CHT1/SLC5A7), choline transporter-like 
proteins (CTLs), organic cation transporters (OCTs), and organic 
cation/carnitine transporters.
A microarray survey of CTL1 revealed that it was expressed 
in cancers of the central nervous system, ovary, breast, prostate, 
and leukemia, while highly expressed in melanoma, renal, and 
colon cancer (139). Functional expression analysis showed that 
the expression of the CTL family was different across different 
cancer cell lines, and that cancer cells expressed at least one set 
of choline transporters to guarantee the import of this essential 
nutrient. Both the expression of choline transporter genes and 
the rate of choline uptake in breast cancer cells were shown to 
be much higher than in the non-malignant human mammary 
epithelial cell (HMEC) line MCF-10A (140). CHT1 mRNA was 
only slightly expressed in the neuroblastoma cell lines SH-SY5Y 
and LA-N-2 (140), while CTL1 was the major choline transporter 
in these cancer cells (141). CHT1 and OCT2 were upregulated 
in breast cancer cell lines as compared to HMEC (142), while 
another study showed that CTL1 and CTL2 were the two genes 
overexpressed in the breast cancer cell line MCF-7 as compared to 
the non-malignant mammary epithelial cell line MCF-10A, and 
CTL2 specifically was detected in human breast cancers by immu-
nohistochemical staining (140). CTL1 was highly overexpressed 
in human pulmonary adenocarcinoma tissues as compared to 
matched normal tissues (143). CTL1 was also the major choline 
transporter that accounts for the enhanced choline uptake in lung 
adenocarcinoma cell lines, the human HT-29 colon carcinoma 
FigURe 5 | Targeting acid sphingomyelinases (ASM) is an effective strategy to overcome drug-resistant cancer through lysosome destabilization-
mediated cell kill. (A) Siramesine and Desipramine, two cationic amphiphilic drugs and inhibitors of ASM, cause lysosomal membrane permeabilization in MCF-7 
cells. The numbers given underneath each image are the respective percentage of cells with lysosomal membrane permeabilization as indicated by cytosolic Alexa 
Fluor 488-dextran staining. Scale bar, 20 µm. (B) Cell death of transformed NIH 3T3-c-srcY527F cells caused by siramesine can be rescued by adding 75 µM ASM 
from Bacillus cereus prior to starting drug treatment. Scale bar, 50 µm. (C) ASM inhibition reverts drug resistance of cancer cells. Siramesine and Desipramine 
treatment of multidrug-resistant (MDR) PC3-MDR or Du145-MDR greatly increased the percentage of cells undergoing apoptotic cell death as evident by 
condensed chromatin when co-treated with docetaxel. **represents P < 0.01, ***represents P < 0.001. Adapted from Petersen Nikolaj et al. (121).
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cell line (144), leukemia cells (140), and human neuroblastoma 
cells (141).
The requirement for an increased supply of choline implies that 
cancer cells may be vulnerable to choline transporter inhibition. 
Organic cation drugs, which likely share the same transporters 
with choline, might inhibit choline uptake, and thereby reduce 
cancer cell viability. The choline analog hemicholinium-3 (HC-3) 
and tetrahexylammonium chloride were reported to inhibit cho-
line uptake and reduce cell proliferation when treating the human 
colon carcinoma cell line HT-29 (144). The Na+/H+ exchanger 
inhibitor dimethylamiloride and various organic cations such 
as quinine, quinidine, desipramine, imipramine, clomipramine, 
diphenhydramine, and fluvoxamine, among others were shown 
to inhibit choline uptake and cell viability in the small cell lung 
carcinoma cell line NCI-H69 (145). In the same study, HC-3 
and CTL1 siRNA were shown to inhibit choline uptake and cell 
viability as well, along with increasing caspase-3/7 activity (145). 
CTL1 inhibitors significantly block choline uptake in the lung 
adenocarcinoma cell lines A549, H1299, and SPC-A-1, and their 
ability to block uptake was closely associated with their efficacy 
in reducing cell proliferation (143). HC-3 also significantly 
inhibited choline uptake in both HL-60 and Jurkat leukemia cells, 
thereby leading to increased caspase-3/7 activity and decreased 
cell viability (140).
The high-affinity choline transporter CHT1 was thought to be 
unique to cholinergic neurons, in which choline is used to synthe-
size the neurotransmitter acetylcholine (ACh) (146). However, 
there is evidence that non-neuronal cholinergic systems exist in 
lung cancers (147, 148), colon adenocarcinoma (149), and leu-
kemia (140). In these cancers, ACh acts as an autocrine or local 
paracrine growth factor that stimulates tumor growth, with mus-
carinic cholinergic receptor subtype M3 or nicotinic cholinergic 
receptors functioning as its receptors (147, 149, 150), which is 
indicated in Figure 6. However, the free choline transported into 
some cells for this non-neuronal ACh synthesis is not dependent 
on CHT1 transport (150–152). Knockdown of CTL4, but not 
other genes in the CTL family, in both lung and colon cancer 
cells significantly decreased ACh secretion and cell growth, 
suggesting that CTL4 is a reasonable target for certain types of 
cancer therapy without affecting neuronal ACh synthesis (150, 
153). CTL1 was reported to be associated with ACh production in 
human neuroblastoma cells (141), but negatively associated with 
FigURe 6 | Choline is an essential nutrient transported into cells by 
choline transporters. In some cancer types such as lung cancers, choline 
that is taken up into cells is converted to acetylcholine, serving as an 
autocrine or paracrine growth factor which stimulates cancer cell growth. 
Alternatively, choline is converted to phosphocholine and ultimately 
phosphatidylcholine, serving as building block to satisfy the increased 
proliferation rate of cancer cells and tumor growth. Abbreviations: ACh, 
acetylcholine; CCT, phosphocholine cytidylyltransferase; CDP-Cho, cytidine 
5′-diphosphocholine; ChAT, choline acetyltransferase; ChKα, choline kinase 
α; Cho, choline; CPT, diacylglycerol cholinephosphotransferase; nAChR, 
nicotinic acetycholine receptor; mAChR, muscarinic acetycholine receptor; 
PC, phosphocholine; PtdCho, phosphatidylcholine.
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ACh secretion from non-small cell lung carcinoma (154). CTL1 
inhibition to reduce ACh production may be an effective way of 
killing cancer cells in certain types of cancer.
Choline transporters are crucial for cells to import extracel-
lular choline. Inhibition of choline transport would likely lead 
to choline deficiency and ceramide accumulation, which in turn 
would trigger apoptosis via p53-independent pathway (140, 155, 
156). Overall, choline transporters, and in particular CTL1 and 
CTL4, are interesting targets for anticancer drug development 
because their inhibition has a great potential to reduce prolifera-
tion and induce apoptosis or block the tumor promoting ACh-M3 
muscarinic cholinergic receptor system. As CHT1 is necessary for 
neuronal ACh biogenesis, as evident by the lethal effect of CHT1 
knockout in mice (157) and the severe toxicity of its inhibitor 
hemicholinium-3 (158), developing inhibitors specific to CTLs 
with low affinity to CHT1 is a must in targeted drug development 
to avoid possible toxic side effects.
gLYCeROPHOSPHODieSTeRASeS
Glycerophosphodiester phosphodiesterases (GDPDs) or 
glycerophosphodiesterases (GDEs) are enzymes that use glyc-
erophosphodiesters as substrates and break them down into 
glycerol 3-phosphate and alcohols (see Figure  7A). Although 
bacterial GDPDs can hydrolyze various glycerophosphodiesters, 
the mammalian genes display substrate preference, and the 
substrates are not limited to glycerophosphodiesters (159). The 
human genome encodes seven members of the GDE family, 
and three of them, as well as their close homologs in mice, were 
reported to hydrolyze glycerophosphodiesters (159). GDE1 dis-
plays substrate preference toward glycerophosphoinositol (GPI), 
while glycerophosphoserine (GPS) and glycerophosphoglycerate 
(GPG) are direct GDE1 substrates as well, and GPE is able to 
block the glycerophosphoinositol phosphodiesterase activity of 
GDE1, but not GPC (160). The two GDPDs: GDPD5 (or GDE2) 
and GDPD6 (or GDE5, GPCPD1) were reported to display 
glycerophosphocholine phosphodiesterase (GPC-PDE) activity 
(161, 162).
GDPD5 was first reported in mice as a GPC-PDE that osmoti-
cally regulates GPC levels in renal medullary cells, in which GPC 
is an abundant and important osmoprotective organic osmolyte 
(161). Phosphorus MRS measurements of MDA-MB-231 breast 
cancer xenografts with constitutively silenced GDPD5 in nude 
mice also displayed an increase in GPC (164). GDPD5 expres-
sion was found to correlate with breast cancer malignancy (165). 
GDPD5, as well as PLD1 and ChKα, were highly expressed in 
estrogen receptor negative (ER−) breast cancers, which also dis-
played higher PC, tCho, and lower GPC in comparison with ER+ 
cases (165). High-resolution 1H MRS analysis of breast cancer cell 
lines in which GDPD5 or GDPD6 were silenced demonstrated 
that GDPD6 has a leading role in regulating the intracellular GPC 
level in breast cancer cells (Figure  7B) (163). siRNA silencing 
of GDPD5 reduced the viability (Figure  7C) and migration 
(Figure 7D) of ER + MCF-7 breast cancer cells, and decreased the 
migration and invasion of triple-negative MDA-MB-231 breast 
cancer cells (163). GDPD5 also has important functions in regulat-
ing neuron differentiation through glycosylphosphatidylinositol-
anchor cleavage of reversion-inducing cysteine-rich protein with 
kazal motifs (RECK) (166), which, further downstream, leads to 
inactivation of the Notch signaling pathway.
GDPD6 was shown to be an Mg2+-dependent GDE that is able 
to hydrolyze GPC and GPE, but does not show activity with GPG, 
GPI, and GPS as substrates (167). The role of GDPD6 in cancer 
was recently identified, demonstrating that GDPD6 expression 
promotes cancer cell migration and invasion through protein 
kinase alpha signaling (162). GDPD6 mRNA levels were shown to 
be increased in metastasizing as compared to non-metastasizing 
endometrial carcinomas, and GDPD6 expression was negatively 
associated with relapse-free survival in endometrial and ovarian 
cancers (162). GDPD6 was overexpressed in endometrial cancers, 
along with ChKα overexpression, resulting in a 70% increase in 
PC levels (16). Microarray analysis of GDPD6-silenced MCF-7 
and OVCAR-3 cells compared to control samples revealed that 
the expression of integrin β1 was reduced, which resulted in 
decreased cell attachment and spreading, while overexpression of 
GDPD6 had the opposite effect (168). The GDPD6 protein con-
tains two conserved domains, which are a carbohydrate-binding 
domain and a catalytic domain conferring GDE enzyme activity. 
GDPD6 was also shown to regulate skeletal muscle development 
in an enzyme activity-independent domain (167). It is not yet 
clear whether the choline-releasing enzymatic activity of GDPD6 
is important for its function in promoting cancer cell migration 
and invasion.
FigURe 7 | gDPD5 and gDPD6, the two glycerophosphocholine phosphodiesterases (gPC-PDes) reported to release choline from 
glycerophosphocholine (gPC), show potential anticancer effects. (A) GPC-PDE enzyme activity is defined as cleaving the choline moiety from GPC and 
thereby generating glycerol-3-phosphate. (B) Transient knockdown of GDPD5 or GDPD6 by siRNA treatment of MDA-MB-231 cells shows that GDPD6 silencing 
leads to a significant elevation of the GPC peak in high-resolution 1H MR spectra from water-soluble metabolites, while GDPD5 silencing marginally increases GPC 
levels in this cell line. (C) GDPD5, but not GDPD6, siRNA shows cytotoxic effect in MCF-7 breast cancer cells indicated by reduced cell numbers following siRNA 
treatment of MCF-7 cells. (D) Both GDPD5 and GDPD6 silencing decreased MCF-7 cell migration detected by scratch assay. Abbreviations: PC, phosphocholine.  
*represents P < 0.05, **represents P < 0.01. Adapted from Cao et al. (163).
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Both GDPD5 and GDPD6 are emerging as potential antican-
cer targets in choline metabolism. Their differing specific roles 
in conferring cancer aggressiveness and degrading GPC are at a 
relatively early stage of investigation and will require additional 
mechanistic and preclinical studies to evaluate their full potential 
as possible drug targets for anticancer therapy.
PHOSPHATiDYLeTHANOLAMiNe 
N-MeTHYLTRANSFeRASe (PeMT)
Phosphatidylethanolamine can be directly converted to PtdCho 
in one step through three methylations of the ethanolamine 
moiety of PtdEtn, which is catalyzed by the enzyme PEMT. This 
enzyme was initially isolated from rat liver and was thought to be 
specific to the liver (169). The first indication that PEMT can sup-
press cancer was the discovery that the growth of rat hepatoma 
cells was suppressed by overexpressing the PEMT gene (170). 
PEMT is highly expressed in normal liver, but its activity was 
negligible in the two hepatoma cell lines and almost diminished 
during chemically induced hepatocarcinogenesis (171, 172), and 
the induced neoplastic phenotype could be partially reversed by 
PEMT cDNA transfection (172). When growing hepatoma cells 
in an animal host, PEMT activity and protein expression were 
barely detected in the fast proliferation stage, while its mRNA 
and protein reappeared in stationary growth stages (173). Forced 
expression of PEMT in McArdle-RH7777 hepatoma cells resulted 
in cell apoptosis (173).
Most early studies of PEMT function were using non-human 
hepatoma cells or chemically induced hepatocarcinogenesis 
models in animals. A later study with clinical samples of human 
hepatocellular carcinomas (HCC) showed that while the PEMT 
gene was intact, its mRNA level was reduced or even absent 
compared to peritumoral normal tissue, which was also observed 
in parallel for PEMT’s enzyme activity (174). PEMT mRNA was 
found to inversely correlate with HCC histological stage, and the 
absence of PEMT mRNA in tumor tissue from cancer patients 
was associated with poor survival (174). While early studies of 
PEMT’s role in cancer were mostly observed in liver cancers, 
more recent studies indicated that PEMT polymorphism is also 
related to breast cancer risk (175). In BRCA1-mutated breast 
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cancer, the PEMT gene undergoes epigenetic repression, and 
hypermethylation of a specific site in the PEMT promoter is 
associated with histological grade and estrogen receptor status 
(176). This finding is consistent with the observation that PtdEtn 
increased with breast tumor grade (6). Another study in small 
cell lung cancer indicated that an increase in PEMT expression 
predicted shorter patient survival time, which is opposite to the 
observations made in liver and breast cancer (177).
The molecular mechanisms by which PEMT expression sup-
presses hepatoma growth are not yet fully understood. One study 
showed that PEMT activity negatively correlated with PtdCho 
synthesis in the Kennedy pathway (178). When PEMT was 
overexpressed in McArdle-RH7777 rat hepatoma cells, cellular 
PtdCho levels did not change even though [methyl-3H]methio-
nine and [3H]ethanolamine were incorporated into PtdCho, 
suggesting that conversion of PtdEtn to PtdCho occurred (178). 
Molecular analysis in this study showed that CTP:phosphocholine 
cytidylyltransferase (CT) activity, which is the rate-limiting step 
in the Kennedy pathway of PtdCho synthesis, decreased (178). 
This was most likely the reason for the unchanged PtdCho levels 
during PEMT overexpression in this study (178). The slowing 
down of the Kennedy pathway while PEMT activity increased 
may have contributed to the reduced cell proliferation rate in 
this study (178). Chemically induced hepatocarcinogenesis and 
growth of hepatoma cells in host animals also demonstrated 
opposing activities of PEMT and CT (171, 173). The overexpres-
sion of PEMT in CBRH-7919 rat hepatoma cells resulted in a 
downmodulation of the PI3K/Akt signaling pathway, which was 
evident by reduced protein levels of c-Met, PDGF receptor, PI3K, 
Akt, and Bcl-2, in addition to decreased phosphorylation of Akt 
Thr308, which was accompanied by elevated cell apoptosis (179).
In summary, PEMT, an enzyme that directly converts PtdEtn 
to PtdCho by sequential methylation, acts as an onco-suppressor. 
Its function and molecular mechanism of tumor suppression, 
and its regulation during carcinogenesis are currently starting to 
emerge and will require more in depth studies.
eTHANOLAMiNe KiNASe (eTNK)
The first step in the Kenney pathway toward de novo synthesis 
of PtdEth or PtdCho is the ATP-dependent phosphorylation 
of free intracellular ethanolamine or free intracellular choline. 
While ChKα does confer dual choline and ETNK activity with 
a preference for choline (180), the conversion of free ethanola-
mine to PE is mainly achieved through ETNK enzyme activity 
(181, 182). There are two genes encoding ETNK enzymes in the 
human genome: ETNK1 (or EKI1) and ETNK2 (or EKI2). Forced 
overexpression of the ETNK1 gene in COS7 cells accelerated the 
Kennedy pathway of PtdEtn synthesis, but did not result in an 
accumulation of PtdEtns due to concomitant faster degradation 
of PtdEtns (183). Interestingly, an ETNK1 recurrent missense 
mutation was frequently found in systemic mastocytosis with 
eosinophilia and chronic myelomonocytic leukemia (184, 185). 
These mutations caused an amino acid change located in the 
kinase domain, which was predicted to disrupt the enzyme’s 
catalytic activity (184, 185). Metabolite measurements revealed 
an averaged 5.2-fold decrease in the PtdEtn/PtdCho ratio of 
ETNK1-mutated atypical chronic myelomonocytic leukemia 
samples as compared to ETNK1 wild-type samples (184). In 
contrast to these findings in leukemia, in different types of human 
testicular cancers, EKI1 co-amplified with DAD-R and SOX5, all 
of which reside in close-by chromosomal regions of the short arm 
of chromosome 12 (12P) (186). The DAD-R gene is thought to be 
clinically relevant in the malignant transformation of testicular 
cancers because of elevated DAD-R expression in testicular 
cancers with 12P amplification, which correlated with invasive 
growth and a reduced level of apoptosis, as compared to testicular 
cancers without 12P amplification (186).
While the roles and functions of ETNKs in cancer are still at an 
early stage of investigation, the product of its enzymatic activity, 
PE, has been known to be elevated in several cancers for decades 
(45, 187). Moreover, synthetic PE has recently been suggested to 
have anticancer effects on melanoma (188), Ehrlich ascites tumor 
(189), and leukemia (190). PE has also been reported to possess 
anti-angiogenic and anti-metastatic activity in lung cancer (191) 
and to induce cell cycle arrest and apoptosis in MCF-7 breast can-
cer cells (192). While the therapeutic effects of PE still need to be 
verified by additional studies and eventually clinical trials, ETNK 
may be an additional target for MRS-monitored anticancer treat-
ment and should be the focus of more research studies in the near 
future. It is also possible that elevated PE levels in several types 
of cancer could be the result of elevated ChKα expression and 
activity levels, which is known to also act on free ethanolamine 
(180). Additional studies are necessary to clarify the involvement 
of ChKα in the elevated tumoral PE levels.
THe FUTURe: TARgeTiNg MULTiPLe 
TARgeTS AND MeTABOLiC NODeS
As our molecular understanding of the different roles of choline 
and ethanolamine phospholipid metabolism enzymes in cancer 
is growing, it will become important to study the interactions 
between these enzymes as well. For example, in aggressive ER− 
breast cancers, GDPD5, PLD1, and ChKα, were simultaneously 
highly expressed, leading to elevated PC and tCho levels (165). 
Moreover, it was recently shown that by silencing ChKα in breast 
cancer cells, PtdCho–PLD1 was in turn upregulated and vice versa 
(88). Only silencing of both enzymes simultaneously increased 
apoptosis in the tested breast cancer cells, supporting the neces-
sity for targeting multiple enzymes in choline phospholipid 
metabolism as a strategy of choice (88). This is also important 
as targeting only one choline metabolic enzyme for anticancer 
treatment may lead to the development of resistance in the treated 
cancer cells more easily as cancer cells are able to adapt to new 
growth environments and thereby acquire resistance.
Once the body of knowledge about the regulation of choline 
and ethanolamine phospholipid enzymes has grown even further, 
it may be worthwhile pursuing systems biology approaches of net-
work analyses to identify the important nodes in these metabolic 
pathways that are the most vulnerable for targeting as anticancer 
treatment strategy. Such types of analyses have already been 
performed for drug design and development (193) and recently 
for tissue-specific metabolic networks, including tumors (194).
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CONCLUSiON
The aberrant choline and ethanolamine phospholipid metabolism 
in cancer has recently further been established and solidified as 
a universal metabolic hallmark of cancer. However, our current 
knowledge of druggable targets in choline metabolism is still 
emerging, with only a few enzymes such as ChKα and PLD1 hav-
ing been explored to a level where a somewhat complete picture 
of their regulation, oncogenic roles, and interaction networks in 
cancer are becoming available. For all other enzymes discussed 
in this review, a lot more basic and translational research is 
required to evaluate the exact molecular roles of PtdCho-PLC, 
SMases, choline transporters, GDEs, PEMT, and ETKN in cancer. 
Metabolic imaging approaches such as MRS and PET are valu-
able tools to help assess the targeting and regulation outcomes 
in these studies and to serve later on as monitoring tools in the 
clinic to assess the response to treatment. Future studies and 
computational modeling approaches to evaluate the interaction 
between choline and ethanolamine metabolic enzymes in cancer 
will be necessary.
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